Preparation for Intravenous Hydralazine
For intravenous hydralazine administration, use the drug immediately after opening the vial, administer as a rapid IV bolus of 20-40 mg directly into the vein, and avoid adding it to infusion solutions or using discolored solutions that have contacted metal. 1
Critical Pre-Administration Checks
Before administering IV hydralazine, verify:
- Visual inspection: Discard any discolored solutions, as hydralazine discolors upon metal contact 1
- Timing: Use immediately after vial opening—do not store opened vials 1
- Route confirmation: IV hydralazine should only be used when oral administration is not possible 1
Dosing Protocol
Standard Adult Dosing
- Initial dose: 20-40 mg as rapid IV bolus directly into vein 1
- Repeat dosing: May repeat as necessary based on blood pressure response 1
- Onset: Blood pressure begins falling within minutes, with maximal decrease at 10-80 minutes 1
Special Populations
- Renal impairment: Lower doses required 1
- Pediatric patients (when used off-label): 1.7-3.5 mg/kg daily divided into 4-6 doses 1
Critical Safety Considerations
Monitor blood pressure frequently after administration 1. The rapid, uncontrolled blood pressure drop with IV hydralazine carries significant risks:
- In severe preeclampsia, continuous IV infusion caused fetal distress requiring cesarean delivery in 5 of 7 patients 2
- Research shows IV hydralazine produces the most significant BP drop among commonly used antihypertensives (13 mmHg MAP reduction) 3
- Avoid continuous infusion—use intermittent bolus dosing only 2
Important Pharmacogenetic Note
NAT2 acetylator status does not affect IV hydralazine pharmacokinetics because there is no first-pass metabolism with intravenous administration 4. Genetic testing is irrelevant for IV dosing decisions 5.
Administration Pitfalls to Avoid
- Never add to infusion solutions: IV hydralazine must be given as direct bolus only 1
- Do not use for asymptomatic hypertension: 69% of IV hydralazine use in one study lacked appropriate indications, leading to hypotension and ICU transfers without improving outcomes 6
- Avoid in increased intracranial pressure: Lowering BP may worsen cerebral ischemia 1
- Watch for metal contact: Use immediately and inspect for discoloration 1
Transition Planning
Most patients can transition to oral hydralazine within 24-48 hours 1. Plan for oral therapy early to minimize IV exposure and associated risks.
Expected Adverse Effects
Common and expected: hypotension and tachycardia 4. Have resuscitation equipment available given the rapid and sometimes excessive BP reduction documented in clinical studies 2, 3.